Learn more about lung cancer at [ Ссылка ]
Erlotinib, gefitinib, and afatinib are commonly used to treat EGFR mutations in non-small-cell lung cancer, according to Robert Winn, MD, director of the Massey Cancer Center at Virginia Commonwealth University. He also discusses second-line drugs, what happens if patients do not respond to targeted therapies, and how biomarker testing for EGFR and other driver mutations can lead to use of additional targeted therapies for lung cancer.
Ещё видео!